Funding for this research was provided by:
Helse Sør-Øst RHF (40093)
Received: 6 July 2022
Accepted: 11 September 2022
First Online: 17 September 2022
: This study was carried out according to the Helsinki declaration, and the included research biobanks have been registered according to national legislation. The study has been approved by the Regional Committee for Medical and Health Research Ethics, which requires that informed consent is obtained from patients enrolled in the study.
: Not applicable.
: GEL certifies that all conflicts of interest are the following: GEL, CJ and RH are named on a patent (WO/2012/052844) proposing <i>VIM</i> as a biomarker for detection of bladder cancer, granted in US (US9797016) and EP (2,630,261). GEL, RW, CJ and HDP are named on a pending PCT patent application (WO/2020/099938) covering the biomarkers published in this study. GEL, MJ and HDP are named on two pending US national applications (US/2019/0221286 and WO/2019/106149) covering the 4Plex control and PoDCall algorithm used in the present study for normalization of DNA methylation ddPCR results. The remaining authors have nothing to disclose.